RAmEx Ars MedicaWorld's most comprehensive source of CD-ROMs, videos, slides and books for medical professionals.
About UsContactShopping CartOrder StatusHelpHome
Title Details
Approved Drug Products With Therapeutic Equivalance Evaluations (FDA Orange Book)
Publisher: U. S. Government Publications
Approved Drug Products With Therapeutic Equivalance Evaluations (FDA Orange Book)Pharmacy & Pharmaceutical Research

See the companion Red Book, which covers pricing.

The publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the Act). Drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal® Tablets and Librax® Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]) are not included in this publication. The main criterion for the inclusion of any product is that the product is the subject of an application with an effective approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products on the List is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the List contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the Act.

Background of the Publication.
To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state stating FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The List was distributed as a proposal in January l979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the Act.

The therapeutic equivalence evaluations in the List reflect FDA's application of specific criteria to the multisource prescription drug products on the List approved under Section 505 of the Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the code appears in the Introduction.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act (1984 Amendments). The 1984 Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Approved Drug Products with Therapeutic Equivalence Evaluations publication and its monthly Cumulative Supplements satisfy this requirement. The Addendum to this publication identifies drugs that qualify under the 1984 Amendments for periods of exclusivity (during which ANDAs or applications described in Section 505(b)(2) of the Act for those drugs may not be submitted for a specified period of time and, if allowed to be submitted, would be tentatively approved) and provides patent information concerning the listed drugs which also may delay the approval of ANDAs or Section 505(b)(2) applications. The Addendum also provides additional information that may be helpful to those submitting a new drug application to the Agency.

Content and Exclusion
The List is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. [Note: Newly approved products are added to parts 1, 2, or 3 of the List, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.]

This publication also includes indices of prescription and OTC drug products by trade or established name (if no trade name exists) and by applicant name (holder of the approved application). All established names for active ingredients generally conform to official compendial names or United States Adopted Names (USAN) as prescribed in (21 CFR 299.4(e)). The latter list includes applicants’ names as abbreviated in this publication; in addition, a list of uniform terms is provided. An Addendum contains drug patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Book Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book Cumulative Supplement), Monthly, 2017, US Domestic Shipment

$345.00  
Approved Drug Products With Therapeutic Equivalance Evaluations (Orange Book Cumulative Supplement), Monthly, 2017, US Domestic Shipment
Format Loose Leaf
Medium Paper
Publisher Catalog Number 917-044-00000-7-SP-DOM
Copyright Year 2016
Length 111 Pages
Journal Frequency J/F/M/A/M/J/J/A/S/O/N/D
Caveat Must Be Used In Conjunction With the Annual. This product is non-returnable. No refunds.

CUMULATIVE SUPPLEMENT CONTENT
The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly CS includes:

  • Generic product ANDA (Abbreviated New Drug Approval) approvals as ofthe date of publication.
  • All product changes received and processed as of the date ofpublication. o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14.The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
  • New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.
  • Patent information, also updated daily in the EOB, is current tothe date of publication.
  • Exclusivity information is updated monthly and current to the date of publication.
This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations;over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appearin the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are formilitary use, or have been discontinued from marketing or that have hadtheir approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the current Edition List will then be added to the "Discontinued Drug Product List" appearing in the current Edition. The current Edition Section 2, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug ProductList are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column.Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.



Similar Products
Back to Top
Featured Products
Acland's Video Atlas of Human Anatomy
Stedman's Plus 2002 Medical/Pharmaceutical Spellchecker Win/Mac CD ROM Nursing 2003 Drug Handbook (Springhouse) The Works of Frank H. Netter MedTerms Illustrated USMLE; Step 1,2,3 Drug Topic Red Book


RAmEx Ars Medica, Inc. | 1714 S. Westgate Av. #2 | Los Angeles, California 90025-3852 | USA
International: 1 310 826 4964 | In the USA: 1 800 633 9281 | Fax: 1 310 826 9674
email ramex.com


Advanced Search
Search By Publisher
Search By Specialty
Search By Media
Search By Title
Shopping Cart
Your Cart is Empty
Home | About | Help | Contact | Policy | Shopping Cart | Order Status
Advanced Search | Publishers | Specialties | Media | Title | RMA | Site Map
© 2017 RAmEx Ars Medica, Inc.

RAmEx Ars Medica, Inc. is a distributor of Scientific Technical Engineering Medical Reference Books Software Videos Online Courses Computers Medical Supplies ramex.com SALE DISCOUNT LOWEST PRICE CLEARANCE

RAmEx Ars Medica, Inc. is a distributor of Scientific Technical Engineering Medical Reference Books Software Videos Online Courses Computers Medical Supplies ramex.com SALE DISCOUNT LOWEST PRICE CLEARANCE

RAmEx Ars Medica, Inc. is a distributor of Scientific Technical Engineering Medical Reference Books Software Videos Online Courses Computers Medical Supplies ramex.com SALE DISCOUNT LOWEST PRICE CLEARANCE

RAmEx Ars Medica, Inc. is a distributor of Scientific Technical Engineering Medical Reference Books Software Videos Online Courses Computers Medical Supplies ramex.com SALE DISCOUNT LOWEST PRICE CLEARANCE